다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Pharmacological research : the official journal of the Italian Pharmacological Society, v.157, 2020년, pp.104859 -
McKee, Dwight L. (Integrative Cancer Consulting) , Sternberg, Ariane (Center and Network for Targeted Oncology) , Stange, Ulrike (Center and Network for Targeted Oncology) , Laufer, Stefan (Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmaceutical Sciences, Eberhard Karls Universitä) , Naujokat, Cord (t, Tü)
AI-Helper
Abstract Outbreak and pandemic of coronavirus SARS-CoV-2 in 2019/2020 will challenge global health for the future. Because a vaccine against the virus will not be available in the near future, we herein try to offer a pharmacological strategy to combat the virus. There exists a number of candidate ...
1 Lu R. Zhao X. Li J. Niu P. Wang B. Wu H. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding Lancet 395 10224 2020 565 574 32007145
2 Zhu N. Zhang D. Wang W. Li X. Yang B. Song J. A novel coronavirus from patients with pneumonia in China N. Engl. J. Med. 383 8 2019 727 733 2020
3 https://coronavirus.jhu.edu/map.html Johns Hopkins University, USA, (2020).
4 Li C. Yang Y. Ren L. Genetic evolution analysis of 2019 novel coronavirus and coronavirus from other species Infect. Genet. Evol. 82 2020 104285 32169673
5 Anthony S.J. Johnson C.K. Greig D.J. Kramer S. Che X. Wells H. Global patterns in coronavirus diversity Virus Evol. 3 1 2017 vex012 28630747
6 Su S. Wong G. Shi W. Liu J. Lai A.C.K. Zhou J. Epidemiology, genetic recombination, and pathogenesis of coronaviruses Trends Microbiol. 24 6 2016 490 502 27012512
7 Tortorici M.A. Veesler D. Structural insights into coronavirus entry Adv. Virus Res. 105 2019 93 116 31522710
8 Hoffmann M. Kleine-Weber H. Schroeder S. Kruger N. Herrler T. Erichsen S. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease receptor Cell March 4 2020 10.1016/j.cell.2020.02.052 pii: S0092-8674(20)30229-4
9 Walls A.C. Park Y.J. Tortorici M.A. Wall A. McGuire A.T. Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein Cell March 6 2020 10.1016/j.cell.2020.02.058 pii: S0092-8674(20)30262-2
10 Wu Y.C. Chen C.S. Chan Y.J. The outbreak of COVID-19: an overview, J. Chin Med. Assoc. 83 2 2020 217 220
11 Zhu N. Zhang D. Wang W. Li X. Yang B. Song J. A novel coronavirus from patients with pneumonia in China N. Engl. J. Med. 382 8 2020 727 733 31978945
12 Tang B. Bragazzi N.L. Li Q. Tang S. Xiao Y. Wu J. An updated estimation of the risk of transmission of the novel coronavirus (2019-nCov) Infect. Dis. Model. 5 2020 248 255 32099934
13 Baez-Santos Y.M. St John S.E. Mesecar A.D. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds Antiviral Res. 115 2015 21 38 25554382
14 Morse J.S. Lalonde T. Xu S. Liu W.R. Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV Chembiochem. 21 5 2020 730 738 32022370
15 Sheahan T.P. Sims A.C. Leist S.R. Schafer A. Won J. Brown A.J. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV Nat. Commun. 11 1 2020 222 31924756
16 Bertram S. Heurich A. Lavender H. Gierer S. Danisch S. Perin P. Influenza and SARS-coronavirus activating proteases TMPRSS2 and HAT are expressed at multiple sites in human respiratory and gastrointestinal tracts PLoS One 7 4 2012 e:35876 22558251
17 Zhou Y. Vedantham P. Lu K. Agudelo J. Carrion R. Nunneley J.W. Protease inhibitors targeting coronavirus and filovirus entry Antiviral Res. 116 2015 76 84 25666761
18 Yamaya M. Shimotai Y. Hatachi Y. Lusamba Kalonji N. Tando Y. Kitajima Y. The serine protease inhibitor camostat inhibits influenza virus replication and cytokine production in primary cultures of human tracheal epithelial cells Pulm. Pharmacol. Ther. 33 2015 66 74 26166259
19 Matsuyama S. Nagata N. Shirato K. Kawase M. Takeda M. Tagushi F. Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2 J. Virol. 84 24 2010 12685-12664
20 Shulla A. Heald-Sargent T. Subramanya G. Zhao J. Perlman S. Gallagher T. A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry J. Virol. 85 2 2011 873 882 21068237
21 Glowacka I. Bertram S. Muller M.A. Allen P. Soilleux E. Pfefferle S. Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response J. Virol. 85 9 2011 4122 4134 21325420
22 Kawase M. Shirato K. van der Hoek L. Taguchi F. Matsuyama S. Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry J. Virol. 86 12 2012 6537 6545 22496216
23 Ohkoshi M. Fujji S. Effect of the synthetic protease inhibitor [N,N-dimethylcarbamoyl-methyl 4-(4-guanidinobenzoyloxy)-phenylacetate] methanesulfate on carcinogenesis by 3-methylcholanthrene in mouse skin J. Natl. Cancer Inst. 71 5 1983 1053 1057 6580482
24 Ohkoshi M. Oka T. Clinical experience with a protease inhibitor [N,N-dimethylcarbamoylmethyl 4-(4-guanidinobenzoyloxy)-phenylacetate] methanesulfate for prevention of recurrence of carcinoma of the mouth and in treatment of terminal carcinoma J. Maxillofac. Surg. 12 4 1984 148 152 6590712
25 Ikeda S. Manabe M. Muramatsu T. Takamori K. Ogawa H. Protease inhibitor therapy for recessive dystrophic epidermolysis bullosa. In vitro effect and clinical trial with camostat mesylate J. Am. Acad. Dermatol. 18 16 1988 1246 1252 3385039
26 Goke B. Stockmann F. Muller R. Lankisch P.G. Creutzfeld W. Effect of a specific serine protease inhibitor on the rat pancreas: systemic administration of camostate and exocrine pancreatic secretion Digestion 30 3 1984 171 178 6209186
27 Adler G. Mullenhoff A. Koop I. Bozkurt T. Goke B. Beglinger C. Stimulation of pancreatic secretion in man by a protease inhibitor (camostate) Eur. J. Clin. Invest. 18 1 2020
28 Sai J.K. Suyama M. Kubokawa Y. Matsumura Y. Inami K. Watanabe S. Efficacy of camostat mesilate against dyspepsia associated with non-alcoholic mild pancreatic disease J. Gastroenterol. 45 3 2010 335 341 1988 98-104 19876587
29 Yamawaki H. Futagami S. Kaneto K. Agawa S. Higuchi K. Murakami M. Camostat mesilate, pancrelipase, and rabeprazole combination therapy improves epigastric pain in early chronic pancreatitis and functional dyspepsia with pancreatic enzyme abnormalities Digestion 99 4 2019 283 292 30391941
30 Ramsey M.L. Nuttall J. Hart P.A. A phase 1/2 trial to evaluate the pharmacokinetics, safety, and efficacy of NI-03 in patients with Chronic pancreatitis: study protocol for a randomized controlled trial on the assessment of camostat treatment in chronic pancreatitis (TACTIC) Trials 20 1 2019 501 31412955
31 NCT02693093, ClinicalTrials.gov, (2016), Feb 26.
32 Iwako M. Ino Y. Motoyoshi A. Ozeki M. Sato T. Kumuri M. Pharmacological studies of FUT-175, nafamostat mesilate. V. Effects on the pancreatic enzymes and experimental acute pancreatitis in rats Jpn. J. Pharmacol. 41 2 1986 155 162 2427760
33 Hiraishi M. Yamazaki Z. Ichikawa K. Kanai F. Idezuki Y. Onishi K. Plasma collection using nafamostat mesilate and dipyridamole as an anticoagulant Int. J. Artif. Organs 11 3 1988 212 216 3403059
34 Hirota M. Shimosegawa T. Kitamura K. Takeda K. Takeyama Y. Mayumi T. Continuous regional arterial infusion versus intravenous administration of the protease inhibitor nafamostat mesilate for predicted severe acute pancreatitis: a multicenter, randomized, open-label, phase 2 trial J. Gastroenterol. 55 3 2020 342 352 31758329
35 Yamamoto M. Matsuyama S. Li X. Takeda M. Kawaguchi Y. Inoue J.I. Identification of nafamostat as a potent inhibitor of middle east respiratory syndrome coronavirus S protein-mediated membrane fusion using the split-protein-based cell-cell fusion assay Antimicrob. Agents Chemother. 60 11 2016 6532 6539 27550352
36 Wang M. Cao R. Zhang L. Yang X. Liu J. Xu M. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro Cell Res. 30 3 2020 269 271 32020029
37 Li W. Moore M.J. Vasilieva N. Sui J. Wong S.K. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronoavirus Nature 426 6965 2003 450 454 14647384
38 Ge X.Y. Li J.L. Xang X.L. Chumura A.A. Zhu G. Epstein J.H. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor Nature 503 7477 2013 535 538 24172901
39 Song W. Gui M. Wang X. Xiang Y. Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2 PLoS Pathol. 14 8 2018 e1007236
40 Turner A.J. Tipnis S.R. Guy J.L. Rice G. Hooper N.M. ACEH/ACE2 is a novel mammalian metallocarboxypeptidase and a homologue of angiotensin-converting enzyme insensitive to ACE inhibitors Can. J. Physiol. Pharmacol. 80 4 2002 346 353 12025971
41 Ben-Zvi I. Kivity S. Langevitz P. Shoenfeld Y. Hydroxychloroquine: from malaria to autoimmunity Clin. Rev. Allergy Immunol. 42 2 2012 145 153 21221847
42 Savarino A. Di Trani L. Donatelli I. Cauda R. Cassone A. New insights into the antiviral effects of chloroquine Lancet Infect. Dis. 6 2 2006 67 69 16439323
43 Yan Y. Zou Z. Sun Y. Li X. Xu K.F. Wei Y. Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model Cell Res. 32 2 2013 300 302
44 Vincent M.J. Bergeron E. Benjannet S. Erickson B.R. Rollin P.E. Ksiazek T.G. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread Virol. J. 2 August 22 2005 69 16115318
45 Al-Bari M.A.A. Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases Pharmacol. Res. Perspect. 5 1 2017 e00293
46 Keyaerts E. Vijge L. Maes P. Neyts J. Van Ranst M. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine Biochem. Biophys. Res. Commun. 323 1 2004 264 268 15351731
47 Yao X. Ye F. Zhang M. Cui C. Huang B. Nui P. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Clin. Infect. Dis. March 9 2020 10.1093/cid/ciaa237 pii: ciaa237.
48 Gao J. Tian Z. Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies Biosci. Trends 14 1 2020 [53]
49 Stahlmann R. Lode H. Medication for COVID-19 ？ an overview of approaches currently under study Arztebl. 117 13 2020 213 219 (2020) 72-73.
50 Gautret P. Lagier J.C. Parola P. Hoang V.T. Meddeb L. Mailhe M. Hydroxychloroquine and azithromycin as a tratment of COVID-19: results of an open-label non-randomized clinical trial Int. J. Antimicrob. Agents March 20 2020 105949 10.1016/j.ijantimicag.2020.105949 32205204
51 Chen Z. Hu J. Zhang Z. Jiang S. Han S. Yan D. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial medRXiv March 31 2020 10.1101/2020.03.22.20040758
52 Zhang Q. Wang Y. Qi C. Shen L. Li J. Clinical trial analysis of 2019-nCoV therapy registered in China J. Med. Virol. February 28 2020 10.1002/jmv.25733
53 Cortegiani A. Ingoglia G. Ippolito M. Giarratano A. Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19 J. Crit. Care March 10 2020 10.1016/j.jcrc.2020.03.005 pii: S0883-9441(20)30390-7
54 Chan K.W. Wong V.T. Tang S.C.W. COVID-19: An update on the epidemiological, clinical, preventive and therapeutic evidence and guidelines of integrative Chinese-Western medicine for the management of 2019 novel coronavirus disease Am. J. Chin. Med. (Gard City N Y) March 13 2020 1 26 10.1142/S0192415X20500378
55 NCT04303507, ClinicalTrials.gov, (2020), Mar 11.
56 NCT04303299, ClinicalTrials.gov, (2020), Mar 11.
57 Bailly C. Cepharanthine: An update of its mode of action, pharmacological properties and medical applications Phytomedicine 62 September 2019 152956 10.1016/j.phymed.2019.152956 31132753
58 Khoja S. Huynh N. Warnecke A.M.P. Asatryan L. Jakowec M.-W. Davies D.L. Preclinical evaluation of avermectins as novel therapeutic agents for alcohol use disorders Psychopharmacology (Berl.) 235 6 2018 1697 1709 29500584
59 Tickell-Painter M. Maayan N. Saunders R. Pace C. Sinclair D. Mefloquine for preventing malaria during travel to endemic areas Cochrane Database Syst. Rev. 10 October 30 2017 10.1002/14651858.CD006491.pub4 CD006491
60 Fan H.H. Wang L.Q. Liu W.L. An X.P. Liu Z.D. He X.Q. Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model Chin. Med. J. March 6 2020 10.1097/CM9.0000000000000797
61 Huang L. Sexton D.J. Skogerson K. Devlin M. Smith R. Sanyal I. Novel peptide inhibitors of angiotensin-converting enzyme 2 J. Biol. Chem. 278 18 2003 15532 15540 12606557
62 Pedersen K.B. Sriramula S. Chhabra K.H. Xia H. Lazartigues E. Species-specific inhibitor sensitivity of angiotensin-converting enzyme 2 (ACE2) and its implication for ACE2 activity assays Am. J. Physiol. Regul. Integr. Comp. Physiol. 301 5 2011 R1293 R1299 21880865
63 Ye M. Wysocki J. Gonzalez-Pacheco F.R. Salem M. Evora K. Garcia-Halpin L. Murine recombinant angiotensin-converting enzyme 2: effect on angiotensin II-dependent hypertension and distinctive angiotensin-converting enzyme 2 inhibitor characteristics on rodent and human angiotensin-converting enzyme 2 Hypertension 60 3 2012 730 740 22777933
64 Guy J.L. Jackson R.M. Jensen H.A. Hooper N.M. Turner A.J. Identification of critical active-site residues in angiotensin-converting enzyme 2 (ACE2) by site-directed mautagenesis FEBS J. 272 14 2005 3512 3520 16008552
65 Han D.P. Penn-Nicholson A. Cho M.W. Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor Virology 350 1 2006 15 25 16510163
66 Mores A. Matziari M. Beau F. Cuniasse P. Yiotakis A. Dive V. Development of potent and selective phosphinic peptide inhibitors of angiotensin-converting enzyme 2, J. Med Chem. 51 7 2008 2216 2226
67 Trask A.J. Groban L. Westwood B.M. Varagic J. Ganten D. Gallagher P.E. Inhibition of angiotensin-converting enzyme 2 exacerbates cardiac hypertrophy and fibrosis in Ren-2 hypertensive rats Am. J. Hypertens. 23 6 2010 687 693 20300067
68 Huentelmann M.J. Zubcevic J. Hernandez Prada J.A. Xiao X. Dimitrov D.S. Raizada M.K. Structure-based discovery of a novel angiotensin-converting enzyme 2 inhibitor Hypertension 44 6 2004 903 906 15492138
69 Haga S. Nagata N. Okamura T. Yamamoto N. Sata T. Yamamoto N. TACE antagonists blocking ACE2 shedding caused by the spike protein of SARS-CoV are candidate antiviral compounds Antiviral Res. 85 3 2010 551 555 19995578
70 Mohler K.M. Sleath P.R. Fitzner J.N. Ceretti D.P. Anderson M. Kerwar S.S. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing Nature 370 6486 1994 218 220 8028669
71 Takahashi M. Terada Y. Nakai I. Nakanishi H. Yoshimura E. Mori S. Role of nicotianamide in the intracellular delivery of metals and plant reproductive development Plant Cell 15 6 2003 1263 1280 12782722
72 Takahashi S. Yoshiya T. Yoshizawa-Kumagaye K. Sugiyama T. Nicotianamide is a novel angiotensin-converting enzyme 2 inhibitor in soybean Biomed. Res. 36 3 2015 219 224 26106051
73 Naujokat C. McKee D.L. The "big five" phytochemicals targeting cancer stem cells: curcumin, EGCG, sulforaphane, resveratrol and genistein Curr. Med. Chem. February 27 2020 10.2174/0929867327666200228110738
74 Monteil V. Kwon H. Prado P. Hagelkruys A. Wimmer R.A. Stahl M. Inhibition of SARS-CoV2 infections in engineered human tissues using clinical-grade soluble human ACE2 Cell 2020 10.1016/j.cell.2020.04.004
75 Warren T.K. Jordan R. Lo M.K. Ray A.S. Mackman R.L. Soloveva V. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys Nature 531 7594 2016 381 385 26934220
76 Lo M.K. Jordan R. Arvey A. Sudhamsu J. Shrivastava-Ranjan P. Hotard A.L. GS-5734 and its parent nucleoside analog inhibit filo-, pneumo-, and paramyxoviruses Sci. Rep. 7 1 2017 43395 28262699
77 Sheahan T.P. Sims A.C. Graham R.L. Menachery V.D. Gralinski L.E. Case J.B. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses Sci. Transl. Med. 9 396 2017 eaal3653 28659436
78 Agostini M.L. Andres E.L. Sims A.C. Graham R.L. Sheahan T.P. Lu X. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease mBio. 9 2 2018 e00221 18 29511076
79 Tchesnokov E.P. Feng J.Y. Porter D.P. Gotte M. Mechanisms of inhibition of Ebola virus RNA-dependent RNA polymerase by remdesivir Viruses 11 4 2019 326
80 Gordon C.J. Tchesnokov E.P. Feng J.Y. Porter D.P. Gotte M. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from middle east respiratory syndrome coronavirus J. Biol. Chem. February 24 2020 10.1074/jbc.AC120.013056
81 de Wit E. Feldmann F. Cronin J. Jordan R. Okumura A. Thomas T. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the 345 rhesus macaque model of MERS-CoV infection Proc. Natl. Acad. Sci. U.S.A. February 13 2020 10.1073/pnas.1922083117
82 Mulangu S. Dodd L.E. Davey R.T. Thsihani Mbaya O. Proschan M. Mukadi D. A randomized, controlled trial of Ebola virus disease therapeutics N. Engl. J. Med. 381 24 2019 2293 2303 31774950
83 Grein J. Ohmagari N. Shin D. Diaz G. Asperges E. Castagna A. Compassionate use of remdesivir for patients with severe COVID-19 N. Engl. J. Med. April 10 2020 10.1056/NEJMoa2007016
84 NCT04252664, ClinicalTrials.gov, (2020), Feb 5.
85 NCT04257656, ClinicalTrials.gov, (2020), Feb 6.
86 NCT04280705, ClinicalTrials.gov, (2020), Feb 21.
87 NCT04292730, ClinicalTrials.gov, (2020), Mar 3.
88 NCT04292899, ClinicalTrials.gov, (2020), Mar 3.
89 NCT04302766, ClinicalTrials.gov, (2020), Mar 10.
90 NCT04314817, ClinicalTrials.gov, (2020), Mar 19.
91 NCT04315948, ClinicalTrials.gov, (2020), Mar 20.
92 Sham H.L. Kempf D.J. Molla A. Marsh K.C. Kumar G.N. Chen C.M. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease Antimicrob. Agents Chemother. 42 12 1998 3218 3224 9835517
93 Benson C.A. Deeks S.G. Brun S.C. Gulick R.M. Eron J.J. Kessler H.A. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients J. Infect. Dis. 185 5 2002 599 607 11865416
94 Corbett A.H. Lim M.L. Kashuba A.D. Kaletra (lopinavir/ritonavir) Ann. Pharmacother. 36 7-8 2002 1193 1203 12086554
95 Chu C.M. Cheng V.C.C. Hung I.F.N. Wong M.M.L. Chan K.H. Chan K.S. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings Thorax 59 3 2004 252 256 14985565
96 Chan J.F. Yao Y. Yeung M.L. Deng W. Bao L. Jia L. Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset J. Infect. Dis. 212 12 2015 1904 1913 26198719
97 Arabi Y.M. Asiri A.Y. Assiri A.M. Aziz Jokhdar H.A. Alothman A. Balkhy H.H. Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial Trials 21 1 2020 8 31900204
98 Cao B. Wang Y. Wen D. Liu W. Wang J. Fan G. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19 N. Engl. J. Med. March 18 2020 10.1056/NEJMoa2001282
99 NCT04255017, ClinicalTrials.gov, (2020), Feb 5.
100 NCT04261907, ClinicalTrials.gov, (2020), Feb 10.
101 NCT04286503, ClinicalTrials.gov, (2020), Feb 27.
102 NCT04295551, ClinicalTrials.gov, (2020), Mar 4.
103 NCT04276688, ClinicalTrials.gov, (2020), Feb 19.
104 NCT04307693, ClinicalTrials.gov, (2020), Mar 13.
105 Blaising J. Polyak S.J. Pecheur E.I. Arbidol as a broad sprctrum antivital: un update Antiviral Res. 107 2014 84 94 24769245
106 Leneva I.A. Russell R.J. Boriskin Y.S. Hay A.J. Characteristics of arbidol-resistant mutants of influenza virus: implications for the mechanism of anti-influenza action of arbidol Antiviral Res. 81 2 2009 132 140 19028526
107 Boriskin Y.S. Pecheur E.I. Polyak S.J. Arbidol: a broad-spectrum antiviral that inhibits acute and chronic HCV infection Virol. J. 3 2006 56 16854226
108 Blaising J. Levy P.L. Polyak S.J. Stanifer M. Boulant S. Pecheur E.I. Arbidol inhibits viral entry by interfering with clathrin-dependent trafficking Antiviral Res. 100 1 2013 215 219 23981392
109 Pecheur E.I. Borisevich V. Halfmann P. Morrey J.D. Smee D.F. Prichard M. The synthetic antiviral drug arbidol inhibits globally prevalent pathogenic viruses J. Virol. 90 6 2016 3086 3092 26739045
110 Hulseberg C.E. Feneant L. Szymanska de Wijs K.M. Kessler N.P. Nelson E.A. Shoemaker C.J. Arbidol and other low-molecular-weight drugs that inhibit Lassa and Ebola viruses J. Virol. 93 8 2019 e02185 18 30700611
111 Wang Z. Yang B. Li Q. Wen L. Zhang R. Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China Clin. Infect. Dis. March 16 2020 10.1093/cid/ciaa272
112 Deng L. Li C. Zeng Q. Liu X. Li X. Zhang H. Arbidol combined with LPV/r versus LPV/r alone against corona virus disease 2019: a retrospective cohort study J. Infect. March 11 2020 10.1016/j.jinf.2020.03.002
113 NCT04255017, ClinicalTrials.gov, (2020), Feb 5.
114 NCT04260594, ClinicalTrials.gov, (2020), Feb 7.
115 NCT04273763, ClinicalTrials.gov, (2020), Feb 18.
116 NCT04286503, ClinicalTrials.gov, (2020), Feb 27.
117 Furuta Y. Takahashi K. Fukuda Y. Kuno M. Kamiyama T. Kozaki K. In vitro and in vivo activities of anti-influenza virus compound T-705 Antimicrob. Agents Chemother. 46 4 2002 977 981 11897578
118 Furuta Y. Komeno T. Nakamura T. (T-705) Favipiravir A broad spectrum inhibitor of viral RNA polymerase Proc. Jpn. Acad., Ser. B, Phys. Biol. Sci. 93 7 2017 449 463
119 Jin Z. Smith L.K. Rajwanshi V.K. Kim B. Deval J. The ambiguous base-pairing and high substrate efficiency of T-705 (favipiravir) ribofuranosyl 5’-triphosphate towards influenza A virus polymerase PLoS One 8 7 2014 e68347
120 Delang L. Abdelnabi R. Neyts J. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses Antiviral Res. 153 2018 85 94 29524445
121 Furuta Y. Takahashi K. Shiraki K. Sakamoto K. Smee D.F. Barnard D.L. T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections Antiviral Res. 82 3 2009 95 102 19428599
122 Sissoko D. Laouenan C. Folkesson E. M´Lebing A.B. Beavogui A.H. Baize S. Experimental treatment with favipiravir for Ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-of-concept trial in Guinea PLoS Med. 13 3 2016 e1001967
123 NCT04310228, ClinicalTrials.gov, (2020), Mar 17.
124 NCT04303299, ClinicalTrials.gov, (2020), Mar 11.
125 Anand K. Ziebuhr J. Wadhwani P. Mesters J.R. Hilgenfeld R. Coronavirus main protease (3CLpro) structure: basis for design of anti-SARS drugs Science 300 5626 2003 1763 1767 12746549
126 Zhang L. Lin D. Sun X. Curth U. Drosten C. Sauerhering L. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors Science March 20 2020 10.1126/science.abb3405
127 Jin Z. Du X. Xu Y. Deng Y. Liu M. Zhao Y. Structure of Mpro from COVID-19 virus and discovery of its inhibitors Nature April 9 2020 10.1038/s41586-020-2223-y
128 Lim H. Min D.S. Park H. Kim H.P. Flavonoids interfere with NLRP3 inflammasome activation Toxicol. Appl. Pharmacol. 355 2018 93 102 29960001
129 Chen I.Y. Moriyama M. Chang M.F. Ichinohe T. Severe acute respiratory syndrome coronavirus viroporin 3a activates the NLRP3 inflammasome Front. Microbiol. 10 50 2019 10.3389/fmicb.2019.00050
130 Zhang B.C. Li Z. Xu W. Xiang C.H. Ma Y.F. Luteolin alleviates NLRP3 inflammasome activation and directs macrophage polarization in lipopolysaccharide-stimulated RAW264.7 cells Am. J. Transl. Res. 10 1 2018 265 273 29423011
131 Chen H. Lin H. Xie S. Huang B. Qian Y. Chen K. Myricetin inhibits NLRP3 inflammasome activation via reduction of ROS-dependent ubiquitination of ASC and promotion of ROS-independent NLRP3 ubiquitination Toxicol. Appl. Pharmacol. 365 2019 19 29 30594691
132 Yamagata K. Hashiguchi K. Yamamoto H. Tagami M. Dietary apigenin reduces induction of LOX-1 and NLRP3 expression, leukocyte adhesion, and acetylated low-density lipoprotein uptake in human endothelial cells exposed to trimethylamine-N-oxide J. Cardiovasc. Pharmacol. 74 6 2019 558 565 31815868
133 Choe J.Y. Kim S.K. Quercetin and ascorbic acid suppress fructose-induced NLRP3 inflammasome activation by blocking intracellular shuttling of TXNIP in human macrophage cell lines Inflammation 40 3 2017 980 994 28326454
134 Lim H. Min D.S. Park H. Kim H.P. Flavonoids interfere with NLRP3 inflammasome activation Toxicol. Appl. Pharmacol. 355 2018 93 102 29960001
135 Fu S. Xu L. Li S. Qiu Y. Liu Y. Wu Z. Baicalin suppresses NLRP3 inflammasome and nuclear factor-kappa B (NF-κB) signaling during haemophilus parasuis infection Vet. Res. 47 1 2016 80 27502767
136 Sun Y. Zhao Y. Yao J. Zhao L. Wu Z. Wang Y. Wogonoside protects against dextran sulfate sodium-induced experimental colitis in mice by inhibiting NF-κB and NLRP3 inflammasome activation Biochem. Pharmacol. 94 2 2015 142 154 25677765
137 Dai W. Bi J. Li F. Wang S. Huang X. Meng X. Antiviral efficacy of lavonoids against enterovirus 71 infection in vitro and in newborn mice Viruses 11 7 2019 625
138 Moghaddam E. Teoh B.T. Sam S.S. Lani R. Hassandarvish P. Chik Z. Baicalin, a metabolite of baicalein with antiviral activity against dengue virus Sci. Rep. 4 2014 5452 24965553
139 Ho T.Y. Wu S.L. Chen J.C. Li C.C. Hsiang C.Y. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction Antiviral Res. 74 2 2007 92 101 16730806
140 Lin S.C. Ho C.T. Chuo W.H. Li S. Wang T.T. Lin C.C. Effective inhibition of MERS-CoV infection by resveratrol BMC Infect. Dis. 17 1 2017 144 28193191
141 Kupferschmidt K. Cohen J. WHO launches global megatrial of the four most promising coronavirus treatments Science March 2 2020 https://www.sciencemag.org/news/2020/03/who-launches-global-megatrial-four-most-promising-coronavirus-treatments
142 Mitja O. Clotet B. Use of antiviral drugs to reduce COVID-19 transmission Lancet Glob. Health March 19 2020 10.1016/S2214-109X(20)30114-5
143 Wolfel R. Corman V.C. Guggemos W. Seilmaier M. Zange S. Muller M.A. Virological assessment of hospitalized patients with COVID-19 Nature April 1 2020 10.1038/s41586-020-2196-x
144 Sheahan T.P. Sims A.C. Zhou S. Graham R.L. Pruijssers A.J. Agostini M.L. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice Sci. Transl. Med. April 4 2020 10.1126/scitranslmed.abb5883
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
출판사/학술단체 등이 한시적으로 특별한 프로모션 또는 일정기간 경과 후 접근을 허용하여, 출판사/학술단체 등의 사이트에서 이용 가능한 논문
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.